Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: May 22, 2017

DrugPatentWatch Database Preview

Gabapentin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for gabapentin and what is the scope of gabapentin patent protection?

Gabapentin
is the generic ingredient in four branded drugs marketed by Sciegen Pharms Inc, Alkem Labs Ltd, Acella Pharms Llc, Invagen Pharms, Ranbaxy, Sun Pharm Inds Ltd, Marksans Pharma, Teva Pharms Usa, Ivax Sub Teva Pharms, Sandoz, Amneal Pharms, Zydus Pharms Usa Inc, Teva, Amneal Pharms Ny, Parke Davis, Teva Pharms, Pfizer Pharms, Mylan Pharms Inc, Sun Pharm Inds, Aci Healthcare Ltd, Depomed Inc, Actavis Elizabeth, Hikma, Aurobindo Pharma Ltd, Alkem, Mylan, Apotex Inc, Taro Pharm, Glenmark Generics, Taro, Hi Tech Pharma, Hikma Pharms, Watson Labs, Tris Pharma Inc, Epic Pharma Llc, and Arbor Pharms Llc, and is included in forty-nine NDAs. There are eighteen patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Gabapentin has sixty-four patent family members in seventeen countries.

There are twenty-six drug master file entries for gabapentin. One hundred and five suppliers are listed for this compound. There are three tentative approvals for this compound.

Summary for Generic Name: gabapentin

Tradenames:4
Patents:18
Applicants:36
NDAs:49
Drug Master File Entries: see list26
Suppliers / Packagers: see list105
Bulk Api Vendors: see list93
Clinical Trials: see list102
Patent Applications: see list6,382
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:gabapentin at DailyMed

Pharmacology for Ingredient: gabapentin

Tentative approvals for GABAPENTIN

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe600MGTABLET;ORAL
► Subscribe► Subscribe800MGTABLET;ORAL
► Subscribe► Subscribe400MGCAPSULE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc
HORIZANT
gabapentin enacarbil
TABLET, EXTENDED RELEASE;ORAL022399-002Dec 13, 2011RXYesNo6,818,787► SubscribeYY ► Subscribe
Depomed Inc
GRALISE
gabapentin
TABLET;ORAL022544-001Jan 28, 2011BXRXYesYes8,252,332► SubscribeY ► Subscribe
Glenmark Generics
GABAPENTIN
gabapentin
TABLET;ORAL077662-001Aug 18, 2006ABRXNoNo► Subscribe► Subscribe
Mylan
GABAPENTIN
gabapentin
CAPSULE;ORAL090158-001Feb 14, 2011ABRXNoNo► Subscribe► Subscribe
Apotex Inc
GABAPENTIN
gabapentin
TABLET;ORAL077661-004Sep 13, 2006ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Uncover prior art in abandoned patent applications and expired patents
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot